Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2025

Genmab — Januar 2025

Planlagt Fastgjort Låst Flyttet Genmab
702 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #417

    And so, we're performing very well for Darzalex and anticipate that to continue. And in fact, with Darzalex, it's our first brand to hit $3 billion in quarterly sales"

    1 Reply Last reply
    0
    • D Offline
      D Offline
      deleted-user
      wrote on sidst redigeret af
      #418

      Darza royalty ender på ca. 800 mio. kr. over budgettet som Genmab startede med i februar 2024. Det er 800 mio. som kommer "igen" årligt indtil 2030 plus årsvæksten der måtte tilgå (uden renters rente og risiko-vurdering), så er NAV Darza, øget med 100 kurspoint på 11 måneder

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #419

        Emily Field
        Barclays Buy Kr.2,100.00 Maintained Today 23-1-25

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #420

          Ram Selvaraju
          H.C. Wainwright Buy $50.00 Reiterated Today 23-1-25

          1 Reply Last reply
          0
          • P Offline
            P Offline
            ProinvestorNEWS
            wrote on sidst redigeret af
            #421

            Claus Henrik Johansen er sundhedsinvestor samt stifter og CEO for investeringsafdelingen "IA Invest Global Health Invest". Han har i mere end 20 år arbejdet med sundhedsaktier og -selskaber.

            Se med, når han giver sit bud på de tre vigtigste temaer de næste 1-3 år. Han fortæller også, hvorfor han mener, man bør kigge i retning af sundhedsaktier, og hvordan man kan opdele de forskellige selskaber i kategorier, når man skal opbygge sin portefølje. Video: https://proinvestor.com/boards/124357

            1 Reply Last reply
            0
            • B Offline
              B Offline
              bikube
              wrote on sidst redigeret af
              #422

              Sanofi får godkendt udfordrer til Genmab-middel i EU. Det siger MedWatch i dag kl7,37.

              1 Reply Last reply
              0
              • L Offline
                L Offline
                lahn1
                wrote on sidst redigeret af
                #423

                Er Carvykti grundt til lidt skuffenede Dara salg i Q4 ?

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote on sidst redigeret af
                  #424

                  Vand på erzo møllen

                  1 Reply Last reply
                  0
                  • Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktør
                    wrote on sidst redigeret af
                    #425

                    Godmorgen 🙂

                    1 Reply Last reply
                    0
                    • L Offline
                      L Offline
                      LP90
                      wrote on sidst redigeret af
                      #426

                      Godmorgen 🙂

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Stroka
                        wrote on sidst redigeret af
                        #427

                        God morgen 🙂

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          ProinvestorNEWS
                          wrote on sidst redigeret af
                          #428

                          Genmab får sakset 15 pct. af kursmålet hos amerikansk børshus https://proinvestor.com/investornyt/1268962/genmab-far-sakset-15-pct-af-kursmalet-hos-amerikansk-borshus

                          1 Reply Last reply
                          0
                          • M Offline
                            M Offline
                            mobbyduck1
                            wrote on sidst redigeret af
                            #429

                            det ligner et hak i tuden i dag, desværre....

                            1 Reply Last reply
                            0
                            • J Offline
                              J Offline
                              JKY_VH
                              wrote on sidst redigeret af
                              #430

                              Ja GS føler åbenbart trang til at lukke en "bæ" ud. Jeg synes ikke umiddelbart at der er nogen forklaring bortset fra usikkerhed omkring Hexa og det er jo ingen nyhed.

                              1 Reply Last reply
                              0
                              • M Offline
                                M Offline
                                mobbyduck1
                                wrote on sidst redigeret af
                                #431

                                genmab er så billig, at man får alt gratis, hvis man trækker Darzalex og egenkapital fra. Det er helt til grin

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #432

                                  New Mount Sinai Trial Reveals Major Advance in Treatment of Aggressive Lymphoma https://www.mountsinai.org/about/newsroom/2025/new-mount-sinai-trial-reveals-major-advance-in-treatment-of-aggressive-lymphoma

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #433

                                    Danish biotech Genmab (CPH: GMAB) today announced it has named Leslie Amendola senior vice president and general manager of its US business. https://www.thepharmaletter.com/genmab-names-us-general-manager https://www.linkedin.com/posts/genmab_newsupdate-activity-7288199613231120386-i8xM/

                                    1 Reply Last reply
                                    0
                                    • Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktør
                                      wrote on sidst redigeret af
                                      #434

                                      Godmorgen 🙂

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #435

                                        why would Genmab sponsor anything for hemophilia care? https://www.surveymonkey.com/r/H7HFWZ5 (could it have something to do with bleeding side effects from Tisotumab?)( i am assuming it is not related to Hemab, why would it go via Genmab
                                        )

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #436

                                          Brian Slomovitz, MD, MS, FACOG
                                          @GynCancerMD

                                          Honored to discuss our practice changing study using tisotumab vedotin in patients recurrent cervical cancer. Led to full FDA approval https://x.com/GynCancerMD/status/1882780591390921153 -Podcast

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper